Compare BridgeBio Pharma Inc (BBIO) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs General Mills, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while General Mills, Inc. trades at $37.9 (market cap $19.89B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 6.55% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GIS | |
|---|---|---|
Market Cap | $16.61B | $19.89B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $51.11 |
52-Week Low | $47.29 | $32.17 |
Enterprise Value | $18.16B | $33.37B |
Dividend Yield | — | 6.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
General Mills (GIS) trades at $36.89, up 2.27% today, with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), though it beat Q2 2026 EPS estimates. Valuation appears attractive with P/E of 9.23 and P/S of 1.08. Recent news highlights cost-saving initiatives and new product launches, while analyst consensus remains cautious with 61% hold ratings.
Outlook: GIS faces headwinds from soft consumer demand and margin pressure, but its cost-saving strategy and dividend yield offer some stability. Risks include competitive threats and high debt levels. The stock presents a value opportunity for income-focused investors if management can execute its turnaround plan effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
